spironolactone, triamterene). The primary risk of eplerenone is hyperkalemia (which can cause serious arrhythmias). Periodic monitoring of potassium levels is recommended for patients at risk of ...

Purpose: The clinical benefits, adverse effects, pharmacokinetics, and recommendations for the appropriate use of the aldosterone antagonists spironolactone and eplerenone in patients with heart ...

This was an open-label, non-controlled study. After a 2-week washout period, patients with PA underwent randomization with the envelop method: 27 patients received SPL (25 mg) and 27 received ...

Inspra, known generically as eplerenone, and the related drug spironolactone are already used to treat patients with more severe heart failure, but the new study, presented at a Chicago meeting of ...

Spironolactone (Aldactone, Pfizer) and eplerenone (Inspra, Pfizer) are the two available aldosterone blockers (or mineralocorticoid receptor antagonists) available for use in the United States.

Agents such as spironolactone or eplerenone will, nevertheless, act as antagonists to the receptor even when the circulating concentrations of aldosterone, its dominant ligand, are not ...

This finding differs from the findings in RALES 1 and can be attributed to the fact that eplerenone has greater selectivity for the mineralocorticoid receptor than does spironolactone, which also ...

Spironolactone is contraindicated in patients with hyperkalemia, Addison's disease, or concomitant use of eplerenone (Inspra). According to its label, spironolactone recipients should undergo ...

Both eplerenone and spironolactone block the effects of aldosterone, a hormone known to damage heart muscle and, in conjunction with another molecule called angiotensin II, cause blood vessel damage.

CHICAGO, IL—Spironolactone given to patients who have undergone PCI ... Jolly, at AHA, pointed to prior studies, like EPHESUS, which showed another MRA, eplerenone, to be better than placebo in ...